Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer

Executive Summary

Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial

You may also be interested in...

Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses

Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18

Wyeth To Re-Submit Viviant This Year, Expects FDA Advisory Review

Merged Pfizer/Wyeth will likely have to choose between Viviant and Fablyn.

Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along

The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts